Abbott (ABT) and Reckitt Benckiser’s (RBGLY) unit Mead Johnson are not responsible for a young boy’s debilitating intestinal disease, a jury found on Thursday, reported Reuters. The ruling in the lawsuit that accused the companies of failing to warn of the risks of premature baby formulas is a victory for the companies following large losses in similar trials, notes the report. Shares of both parent companies’ stocks are trading higher on Friday following the ruling.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Raymond James says Edwards’ EARLY TAVR data also positive for Medtronic, Abbott
- Abbott initiates clinical trial of its CardioMems in advanced heart failure
- Abbott price target raised to $130 from $115 at Mizuho
- Abbott price target raised to $146 from $143 at UBS
- Abbott price target raised to $133 from $131 at Piper Sandler